e6011
Small moleculeexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01731275)
Timeline
Indications
Mechanism of action
- C-X3-C chemokine receptor 1INHIBITOR
CX3CR1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- e6011
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03733314 | Phase 2 | Apr 25, 2019 | EA Pharma Co., Ltd. |
| NCT03092765 | Phase 2 | Mar 21, 2017 | EA Pharma Co., Ltd. |
| NCT02960490 | Phase 2 | Nov 26, 2016 | Eisai |
| NCT02960438 | Phase 2 | Nov 2, 2016 | Eisai |
| NCT02249078 | Phase 1 | Dec 1, 2014 | Eisai |
| NCT02196558 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2014 | Eisai |
| NCT02039063 | Phase 1/Phase 2 (Phase 2) | May 14, 2014 | Eisai |
| NCT02146261 | Phase 1 | Sep 1, 2013 | Eisai |
| NCT01731275 | Phase 1 | Aug 1, 2012 | Eisai |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 7 | 7 | 2 | 2012 |
| EA Pharma Co., Ltd. | For profit | 2 | 2 | 1 | 2017 |
2 organizations
Page 1 / 1